Apomorphine may still outpace ropinirole for canine emesis

A growing body of evidence is sharpening the choice between two common canine emetics: extra-label apomorphine and FDA-approved ophthalmic ropinirole. A 2024 emergency department study found IV apomorphine outperformed ropinirole eye drops on first-dose success, speed, and need for rescue antiemetics, with 99% first-dose success for apomorphine versus 81% for ropinirole, and median time to first emesis of 1.6 minutes versus 8.6 minutes. In that prospective randomized trial at two specialty hospitals, 132 client-owned dogs with suspected toxin or foreign-body ingestion were enrolled, and dogs that did not vomit within 20 minutes could receive a second identical dose. But other recent studies, including a 2023 clinical trial in client-owned dogs and a 2025 crossover study in healthy dogs, suggest ropinirole can still achieve high overall emetic success, especially when a second dose is allowed. Ropinirole remains the only FDA-approved emetic for dogs in the U.S., marketed as Clevor since its 2020 approval. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary teams handling toxin or foreign-body ingestions, the distinction is practical. Apomorphine appears faster and more reliable when rapid gastric decontamination is the priority, but it is used extra-label in the U.S. and can be administered by several routes. Ropinirole offers an on-label option with ophthalmic dosing, though published data suggest clinicians should be prepared for slower onset, ocular redness, more prolonged vomiting in some dogs, and a higher likelihood of antiemetic rescue in emergency settings. Rescue therapy also matters operationally: maropitant is commonly used after apomorphine, and clinics may soon have another injectable option, with Dechra saying its FDA-approved maropitant product Emeprev will be available in early 2026 as a bioequivalent injectable that does not require refrigeration and is formulated with benzyl alcohol to reduce injection pain in dogs. Guidance from Illinois notes both drugs have a place when emesis is appropriate, but patient selection, timing since ingestion, airway protection, and contraindications still drive the decision more than convenience alone. (vetmed.illinois.edu)

What to watch: Expect more discussion around protocol selection in emergency and general practice as newer comparative data are weighed against ropinirole’s regulatory advantage and ease of use, and as practices consider how antiemetic rescue options fit into those workflows. (pubmed.ncbi.nlm.nih.gov)